ArticleCrohn's & colitis 3602026

Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab.

Justin Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.